bluuebunny/crossref_metadata_2025 huggingface dataset:
Exploring the Caregiver Role after Deep Brain Stimulation Surgery for Parkinson’s Disease: A Qualitative Analysis
Authors: Shahmoon Suzette , Limousin Patricia , Jahanshahi Marjan
Published: April 2023

This pilot study aimed to explore how caregiver spouses make sense of themselves one and five years after their partner’s deep brain stimulation (DBS) surgery for Parkinson’s disease. 16 spouse (8 husbands and 8 wives) caregivers were recruited for the interview. Eight struggled to reflect on their own lived experience and primarily focused on the impact of PD on their partners, such that their transcripts were no longer viable for interpretative phenomenological analysis (IPA). A content analysis showed (1) how these 8 caregivers shared less than half as many self-reflections than the other caregivers, (2) that there was a bias to reflect on their partner’s experience answering the opening question, (3) the bias continued when answering subsequent questions, and (4) there was a lack of awareness of this bias. No other patterns of behaviour or themes were able to be extracted. The remaining 8 interviews were transcribed and analysed using IPA. This analysis discovered 3 inter-related themes: (1) DBS allows carers to question and shift the caregiver role, (2) Parkinson’s unites and DBS divides, and (3) seeing myself and my needs, DBS enhances visibility. How these caregivers interacted with these themes depended on when their partners were operated. The results suggested that spouses maintained the role of caregiver one year post DBS because they struggle to identify themselves in any other way but were more comfortable reassociating into the role of spouse 5 years post surgery. Further inquiry into caregiver and patient identity roles post DBS is recommended as a means of supporting their psychosocial adjustment after surgery.
Optimizing the Transfer Process of Air-Rail Integration Services: A Simulation Approach
Authors: Jiang Fan , Yang Min , Huang Shiyu
Published: April 2023

With the progress of regional integration in China and the growth of passenger travel demand, a single travel mode has been unable to meet passengers’ cross-regional, multimodal, and personalized travel needs. Air-rail integration service (ARIS) is gradually catching on with travellers. Compared with developed countries, ARIS remains in its infancy in China, with a low penetration rate. Against this backdrop, this study presents an SP survey of ARIS passengers at Shijiazhuang Zhengding International Airport as an example and analyses the factors affecting their transfer process using multiple ordinal logistic regression. The satisfaction analysis results help to construct a simulation model of ARIS of Shijiazhuang Zhengding International Airport by using AnyLogic to verify the optimization effect. The research results show a significant impact on the ARIS transfer process by gender, education, occupation, travel mode, travel cost, location of the shuttle bus, arrival frequency of shuttle bus, manual baggage check-in service, self-service check-in, and the performance of security check equipment. The adoption of optimization measures will reduce ARIS shuttle bus, baggage check-in, and security check-in times by 68%, 50%, and 45%, respectively.
Data from Neighborhood Socioeconomic Status and Racial and Ethnic Survival Disparities in Oral Cavity and Laryngeal Cancer
Authors: Liu Yupeng , Zhong Lydia , Puram Sidharth V. , Mazul Angela L.
Published: April 2023

AbstractBackground:
Oral cavity cancer (OCC) and laryngeal cancer are among the most common cancers worldwide. This study investigated survival in non-Hispanic (NH) Black, NH White, Asian, and Hispanic patients with OCC and laryngeal cancer of low, intermediate, and high neighborhood socioeconomic status (nSES).
Methods:
We used data from the SEER 18 Census Tract-level SES and Rurality Database of the National Cancer Institute to create cohorts of OCC and laryngeal cancer patients from 2013 to 2018. Univariate survival analysis was performed with Kaplan–Meier curves and log-rank P values by nSES and then the cross-classification of race, ethnicity, and nSES. We used Cox proportional hazards regression model for multivariable analysis.
Results:
Higher nSES was associated with better OCC survival for NH White, NH Black, and Asian patients, and better laryngeal cancer survival for NH White, NH Black, Hispanic, and Asian patients. In the multivariable analyses of both OCC and laryngeal cancer survival, NH Black patients had worse survival than NH White patients in the high nSES tertile. NH Black patients with OCC were at higher risk of death than NH White patients at all nSES levels. Conversely, Asian patients with laryngeal cancer demonstrated better survival than other races within the high nSES.
Conclusions:
Overall survival differs between racial and ethnic groups of similar nSESs. These health disparities in patients with OCC and laryngeal cancer reflect broader inequities in the cancer control continuum.
Impact:
The cross-classification of race, ethnicity, and nSES revealed disparities in the 5-year overall survival of patients with OCC and laryngeal cancer and highlights the importance of intersectionality in the discussion of health equity.
Supplementary Figure 5 from Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells
Authors: Ewton Daina Z. , Hu Jing , Vilenchik Maria , Deng Xiaobing , Luk Kin-chun , Polonskaia Ann , Hoffman Ann F. , Zipf Karen , Boylan John F. , Friedman Eileen A.
Published: April 2023

PDF file - 78K
Supplementary Table 6 from Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
Authors: Moreaux Jérôme , Rème Thierry , Leonard Wim , Veyrune Jean-Luc , Requirand Guilhem , Goldschmidt Hartmut , Hose Dirk , Klein Bernard
Published: April 2023

PDF file - 74K, Cox univariate and multivariate analysis of OS in HM and TT2 patients' cohorts.
Supplementary Table 4 from Development of Gene Expression–Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors
Authors: Moreaux Jérôme , Rème Thierry , Leonard Wim , Veyrune Jean-Luc , Requirand Guilhem , Goldschmidt Hartmut , Hose Dirk , Klein Bernard
Published: April 2023

PDF file - 54K, Genes underexpressed in decitabine treated HMCLs. Five HMCLs were cultured with or without 0.5 μM decitabine for 7 days and gene expression was profiled with Affymetrix U133 plus 2.0. Genes significantly differentially expressed between control and decitabine treated cells were identified using SAM supervised paired analysis with a 5% false discovery rate. When a gene was interrogated by several probe sets, we used the probe set yielding to a maximum variance across control and decitabine treated cells.
Supplementary Figure 5 from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of Nf1-Deficient Astrocytes
Authors: Banerjee Sutapa , Gianino Scott M. , Gao Feng , Christians Uwe , Gutmann David H.
Published: April 2023

Supplementary Figure 5 from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of Nf1-Deficient Astrocytes
Supplementary Figure 4 from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of Nf1-Deficient Astrocytes
Authors: Banerjee Sutapa , Gianino Scott M. , Gao Feng , Christians Uwe , Gutmann David H.
Published: April 2023

Supplementary Figure 4 from Interpreting Mammalian Target of Rapamycin and Cell Growth Inhibition in a Genetically Engineered Mouse Model of Nf1-Deficient Astrocytes
Supplementary Figure 2 from The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts
Authors: Bello Ezia , Taraboletti Giulia , Colella Gennaro , Zucchetti Massimo , Forestieri Daniele , Licandro Simonetta A. , Berndt Alexander , Richter Petra , D'Incalci Maurizio , Cavalletti Ennio , Giavazzi Raffaella , Camboni Gabriella , Damia Giovanna
Published: April 2023

PDf file - 30KB, Survival curves of MDA-MB-231 bearing mice treated with E-3810, PTX and their combination.
Supplementary Figures 1 through 8 from 177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy
Authors: Reber Josefine , Haller Stephanie , Leamon Christopher P. , Müller Cristina
Published: April 2023

PDF - 569KB, Figure S1: Chemical structures of the compounds applied in this study. Figure S2: Results of the internalization studies of 177Lu-EC0800 performed with FR-positive and FR-negative tumor cell lines Figure S3: Results of a clonogenic assay performed with 177Lu-EC0800 with/without co-application of folic acid using KB and IGROV-1 tumor cells Figure S4: Representation of the area under the curve (AUC) necessary to determine the absorbed dose to the tumors and kidneys. Figure S5: Results of the biodistribution data obtained in KB tumor bearing nude mice injected with 3H-pemetrexed Figure S6: Graphs representing the body weight and survival of mice treated with pemetrexed compared to untreated control mice. Figure S7: Distribution of the cell fractions in a particular cell cycle phase after treatment with 177Lu-EC0800, PMX or both of these agents. Figure S8: Graphs representing the apoptotic fraction of KB and IGROV-1 cells after treatment with 177Lu-EC0800, PMX or both of these agents.
Supplementary Table 8 from Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities
Authors: Craig David W. , O'Shaughnessy Joyce A. , Kiefer Jeffrey A. , Aldrich Jessica , Sinari Shripad , Moses Tracy M. , Wong Shukmei , Dinh Jennifer , Christoforides Alexis , Blum Joanne L. , Aitelli Cristi L. , Osborne Cynthia R. , Izatt Tyler , Kurdoglu Ahmet , Baker Angela , Koeman Julie , Barbacioru Catalin , Sakarya Onur , De La Vega Francisco M. , Siddiqui Asim , Hoang Linh , Billings Paul R. , Salhia Bodour , Tolcher Anthony W. , Trent Jeffrey M. , Mousses Spyro , Von Hoff Daniel , Carpten John D.
Published: April 2023

XLSX file - 273K, Somatic genic focal copy number changes in mTNBC
Supplementary Figure 3 from Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion
Authors: Saintigny Pierre , Peng Shaohua , Zhang Li , Sen Banibrata , Wistuba Ignacio I. , Lippman Scott M. , Girard Luc , Minna John D. , Heymach John V. , Johnson Faye M.
Published: April 2023

PDF file, 48K, Ephs and eprins in vivo.
Supplementary Figure 1 from Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion
Authors: Saintigny Pierre , Peng Shaohua , Zhang Li , Sen Banibrata , Wistuba Ignacio I. , Lippman Scott M. , Girard Luc , Minna John D. , Heymach John V. , Johnson Faye M.
Published: April 2023

PDF file, 31K, EPHA4 in the Boston cohort.
Supplementary Table 2 from A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo
Authors: Kuruma Hidetoshi , Matsumoto Hiroaki , Shiota Masaki , Bishop Jennifer , Lamoureux Francois , Thomas Christian , Briere David , Los Gerrit , Gleave Martin , Fanjul Andrea , Zoubeidi Amina
Published: April 2023

PDF, 49K, MDV3100 and Compound 30 IC50 in LNCaP and C4-2 cel
Supplementary Figure S1 from Antitumor Activity and Pharmacodynamic Biomarkers of a Novel and Orally Available Small-Molecule Antagonist of Inhibitor of Apoptosis Proteins
Authors: Sumi Hiroyuki , Yabuki Masato , Iwai Kenichi , Morimoto Megumi , Hibino Ryosuke , Inazuka Masakazu , Hashimoto Kentaro , Kosugi Yohei , Aoyama Kazunobu , Yamamoto Shunsuke , Yoshimatsu Mie , Yamasaki Hideki , Tozawa Ryuichi , Ishikawa Tomoyasu , Yoshida Sei
Published: April 2023

PDF file - 88KB, X-ray crystal structure of T-3256336 and Functional inhibition potency on caspase-7 and caspase-9
Supplementary Table 3 from Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
Authors: Guzman Monica L. , Yang Neng , Sharma Krishan K. , Balys Marlene , Corbett Cheryl A. , Jordan Craig T. , Becker Michael W. , Steidl Ulrich , Abdel-Wahab Omar , Levine Ross L. , Marcucci Guido , Roboz Gail J. , Hassane Duane C.
Published: April 2023

PDF - 67K, DAVID pathway analysis for downregulated genes (BBID).
Supplementary Table 1 from Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
Authors: Guzman Monica L. , Yang Neng , Sharma Krishan K. , Balys Marlene , Corbett Cheryl A. , Jordan Craig T. , Becker Michael W. , Steidl Ulrich , Abdel-Wahab Omar , Levine Ross L. , Marcucci Guido , Roboz Gail J. , Hassane Duane C.
Published: April 2023

PDF - 71K, DAVID pathway analysis for downregulated genes (BioCarta pathways).
Supplementary Figure 4 from Disruption of STAT3 by Niclosamide Reverses Radioresistance of Human Lung Cancer
Authors: You Shuo , Li Rui , Park Dongkyoo , Xie Maohua , Sica Gabriel L. , Cao Ya , Xiao Zhi-Qiang , Deng Xingming
Published: April 2023

PDF file - 109K, Niclosamide-induced growth inhibition is diminished after specific knockdown of STAT3.
Supplementary Data from Decreased miR-340 Expression in Bone Marrow Is Associated with Liver Metastasis of Colorectal Cancer
Authors: Takeyama Hiroshi , Yamamoto Hirofumi , Yamashita Shinya , Wu Xin , Takahashi Hidekazu , Nishimura Junichi , Haraguchi Naotsugu , Miyake Yasuhiro , Suzuki Rei , Murata Kohei , Ohue Masayuki , Kato Takeshi , Takemasa Ichiro , Mizushima Tsunekazu , Ishii Hideshi , Mimori Koshi , Doki Yuichiro , Mori Masaki
Published: April 2023

PDF - 364K, List of microRNA array results.
Supplementary Figures 1 and 2 from Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma
Authors: Han Kyung Seok , Li Na , Raven Peter A. , Fazli Ladan , Ettinger Susan , Hong Sung Joon , Gleave Martin E. , So Alan I.
Published: April 2023

Figure S1. Expression and localization of ILK protein and EMT-related molecular markers in normal renal epithelial cells and RCC cells. Figure S2. Anti-angiogenic effects of in vivo knockdown of ILK in orthotopic RCC xenografts.
Legends for supplmentary figures from Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma
Authors: Han Kyung Seok , Li Na , Raven Peter A. , Fazli Ladan , Ettinger Susan , Hong Sung Joon , Gleave Martin E. , So Alan I.
Published: April 2023

Figure S1. Expression and localization of ILK protein and EMT-related molecular markers in normal renal epithelial cells and RCC cells. Figure S2. Anti-angiogenic effects of in vivo knockdown of ILK in orthotopic RCC xenografts.
Supplementary Figure 1 from Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti–Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody
Authors: Traini Sara , Piccolo Enza , Tinari Nicola , Rossi Cosmo , La Sorda Rossana , Spinella Francesca , Bagnato Anna , Lattanzio Rossano , D'Egidio Maurizia , Di Risio Annalisa , Tomao Federica , Grassadonia Antonino , Piantelli Mauro , Natoli Clara , Iacobelli Stefano
Published: April 2023

PDF file - 48KB, SP-2 inhibits growth of ovarian cancer and melanoma xenografts.
Supplementary Figure 3 from 1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling
Authors: Chen Ping-Tsung , Hsieh Ching-Chuan , Wu Chun-Te , Yen Tzu-Chen , Lin Paul-Yang , Chen Wen-Cheng , Chen Miao-Fen
Published: April 2023

Supplementary Figure 3. Effects of blocking IL-6 on tumor growth and EMT in vitro
Supplementary Methods and Supplementary Figures 1 through 9 from A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo
Authors: Abulwerdi Fardokht , Liao Chenzhong , Liu Meilan , Azmi Asfar S. , Aboukameel Amro , Mady Ahmed S.A. , Gulappa Thippeswamy , Cierpicki Tomasz , Owens Scott , Zhang Tao , Sun Duxin , Stuckey Jeanne A. , Mohammad Ramzi M. , Nikolovska-Coleska Zaneta
Published: April 2023

PDF - 3347KB, Synthesis and characterization of the lead compound 1 (UMI-59) and its analog 2 (UMI-77), additional details for used methods, and nine supplementary figures.
Supplementary Figure 1 from 1α,25-Dihydroxyvitamin D3 Inhibits Esophageal Squamous Cell Carcinoma Progression by Reducing IL6 Signaling
Authors: Chen Ping-Tsung , Hsieh Ching-Chuan , Wu Chun-Te , Yen Tzu-Chen , Lin Paul-Yang , Chen Wen-Cheng , Chen Miao-Fen
Published: April 2023

Supplementary Figure 1. Effects of Calcitriol on tumor cell proliferation in vitro
Supplementary Materials and Methods from Chloroquine Targets Pancreatic Cancer Stem Cells via Inhibition of CXCR4 and Hedgehog Signaling
Authors: Balic Anamaria , Sørensen Morten Dræby , Trabulo Sara Maria , Sainz Bruno , Cioffi Michele , Vieira Catarina R. , Miranda-Lorenzo Irene , Hidalgo Manuel , Kleeff Joerg , Erkan Mert , Heeschen Christopher
Published: April 2023

PDF - 147K, Supplementary methods including related references.
Supplementary Table 2 from A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models
Authors: Yin Tinggui , Lallena Maria J. , Kreklau Emiko L. , Fales Kevin R. , Carballares Santiago , Torrres Raquel , Wishart Graham N. , Ajamie Rose T. , Cronier Damien M. , Iversen Phillip W. , Meier Timothy I. , Foreman Robert T. , Zeckner Douglas , Sissons Sean E. , Halstead Bart W. , Lin Aimee B. , Donoho Gregory P. , Qian Yuewei , Li Shuyu , Wu Song , Aggarwal Amit , Ye Xiang S. , Starling James J. , Gaynor Richard B. , de Dios Alfonso , Du Jian
Published: April 2023

XLSX - 54K, Table S2. 261 probsets gene signature in sens and res cell lines in Excel format.
Supplementary Figure 1 from Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells
Authors: Karpel-Massler Georg , Westhoff M.-Andrew , Zhou Shaoxia , Nonnenmacher Lisa , Dwucet Annika , Kast Richard E. , Bachem Max G. , Wirtz Christian R. , Debatin Klaus-Michael , Halatsch Marc-Eric
Published: April 2023

PDF file - 99 KB, A, graphs demonstrating IC50 for erlotinib and NSC23766 in U87MG, A172MG, T98MG, PC38 and PC40 cells; B, table showing IC50 and IC25 values for K252a, HhAntag, PD173074, pifithrin and cyclosporine.
Supplementary Table 1 from Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus
Authors: Liu Yingmiao , Starr Mark D. , Brady John C. , Rushing Christel , Bulusu Anuradha , Pang Herbert , Honeycutt Wanda , Amara Anthony , Altomare Ivy , Uronis Hope E. , Hurwitz Herbert I. , Nixon Andrew B.
Published: April 2023

The change from baseline to C2D1 and C3D1 for each biomarker was determined across all patients. Biomarker change was statistically analyzed using Wilcoxon signed rank tests and the corresponding p-values, as well as the direction of change, are presented. As shown, Ang-2 levels decreased from baseline to C2D1 and baseline to C3D1; these changes were found to be statistically significant, p < 0.0001. Also, the directionality of change noted for Ang-2 at C2D1 and C3D1 was in the same direction (i.e., down). It should be noted that all biomarkers evaluated exhibited the same directionality of change at both C2D1 and C3D1. While many biomarkers exhibited consistent change at both time points, some biomarkers only exhibited statistically significant change at the C2D1 timepoint (i.e., D-dimer).
Supplementary Figure 4 from Phosphoproteomics of MAPK Inhibition in BRAF-Mutated Cells and a Role for the Lethal Synergism of Dual BRAF and CK2 Inhibition
Authors: Parker Robert , Clifton-Bligh Roderick , Molloy Mark P.
Published: April 2023

PDF file - 214K, Response to combinatorial MAPK1/CK2 inhibition in melanoma cells.
Supplementary Table 1 from Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro
Authors: Wu Xuping , Sooman Linda , Wickström Malin , Fryknäs Mårten , Dyrager Christine , Lennartsson Johan , Gullbo Joachim
Published: April 2023

PDF file - 33K, Table S1. Interactions between PPP and conventional anticancer agents in the ESCC lines.
Supplementary Figure 5 from Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro
Authors: Wu Xuping , Sooman Linda , Wickström Malin , Fryknäs Mårten , Dyrager Christine , Lennartsson Johan , Gullbo Joachim
Published: April 2023

PDF file - 100K, Figure S5 The activity of PPP correlated significantly (p<0.05) with that of tubulin destabilization agents PPT, colchicine, and vinorelbine, but not with that of the other tested drugs in eight lung cancer cell lines.
Supplementary Figure 1 from Alternative Cytotoxic Effects of the Postulated IGF-IR Inhibitor Picropodophyllin In Vitro
Authors: Wu Xuping , Sooman Linda , Wickström Malin , Fryknäs Mårten , Dyrager Christine , Lennartsson Johan , Gullbo Joachim
Published: April 2023

PDF file - 25K, Figure S1 Molecular structures of picropodophyllin (PPP) and podophyllotoxin (PPT).
Supplementary Figure 3 from Downregulation of Hepatoma-Derived Growth Factor Contributes to Retarded Lung Metastasis via Inhibition of Epithelial–Mesenchymal Transition by Systemic POMC Gene Delivery in Melanoma
Authors: Tsai Han-En , Liu Guei-Sheung , Kung Mei-Lang , Liu Li-Feng , Wu Jian-Ching , Tang Chia-Hua , Huang Ching-Hui , Chen San-Cher , Lam Hing-Chung , Wu Chieh-Shan , Tai Ming-Hong
Published: April 2023

PDF file - 1237K, Supplementary Figure 3. POMC gene transfer inhibited neovascularization of metastatic melanoma in vivo. (A) Growth of metastatic GFP-B16-F10 cells in lung was observed by merging the images of GFP (green) and rhodamine label-dextran (red). (B) Blood vessels were labeled by an antibody directed against CD31, a specific marker of endothelial cells. The number of blood vessels within the nodules was counted by image analysis. (Magnification, 4x and Bar, 1.0 mm; 20x and Bar, 200 μm) (n = 5; **: p < 0.01)
Supplementary Figure 1 from Expression of the miR200 Family of microRNAs in Mesothelial Cells Suppresses the Dissemination of Ovarian Cancer Cells
Authors: Sugiyama Kazuya , Kajiyama Hiroaki , Shibata Kiyosumi , Yuan Hong , Kikkawa Fumitaka , Senga Takeshi
Published: April 2023

PDF - 151K, Depletion of FN1 does not affect cancer cell proliferation and promoter activity of MMPs by TGFbeta-stimulated HPMCs. (A) HPMCs were transfected with control or FN1 siRNA, and 24 h later, cells were incubated with or without TGFbeta for 48 h. ES-2 and SKOV3 cells that constitutively expressed luciferase were seeded onto the HPMCs . Cells were lysed 24, 48, and 72 h after cell seeding, and luciferase activity was measured. (B) ES-2 and SKOV3 cells were transfected with pGL4, pGL4-MMP-2/promoter or pGL4-MMP-9/promoter together with pRLTK-luc, and 24 h later, the cells were seeded onto HPMCs treated as in (A). The cells were incubated for 24 h, and then, luciferase activity was measured.
Supplementary Figure 3 from Identification, Mechanism of Action, and Antitumor Activity of a Small Molecule Inhibitor of Hippo, TGF-β, and Wnt Signaling Pathways
Authors: Basu Dipanjan , Lettan Robert , Damodaran Krishnan , Strellec Susan , Reyes-Mugica Miguel , Rebbaa Abdelhadi
Published: April 2023

PDF - 218K, Effect of C19 on ligand induced activation of EMT pathways and cell migration.
Supplementary information from Selective Delivery of PEGylated Compounds to Tumor Cells by Anti-PEG Hybrid Antibodies
Authors: Tung Hsin-Yi , Su Yu-Cheng , Chen Bing-Mae , Burnouf Pierre-Alain , Huang Wei-Chiao , Chuang Kuo-Hsiang , Yan Yu-Ting , Cheng Tian-Lu , Roffler Steve R.
Published: April 2023

Supplementary methods, supplementary table S1:EC50 concentrations of mouse anti-PEG antibodies binding to various PEG molecules, supplementary table S2:Kinetic constants for binding of humanized hybrid antibodies to HER2 ECD and PEG5K, supplementary figure legends
Supplementary Methods, Supplementary Figures 1 to 9, and Supplementary Tables 1 to 3 from Enhancement of the Tumor Penetration of Monoclonal Antibody by Fusion of a Neuropilin-Targeting Peptide Improves the Antitumor Efficacy
Authors: Shin Tae-Hwan , Sung Eun-Sil , Kim Ye-Jin , Kim Ki-Su , Kim Se-Ho , Kim Seok-Ki , Lee Young-Don , Kim Yong-Sung
Published: April 2023

PDF - 2613K, Figure S1: Structural analysis of NRP1, NRP2, and Sema3A, and their interactions to facilitate the understanding of the interactions between Sema3A and NRP1/2. Figure S2: SDS-PAGE analyses of the purified proteins showing that NRP1/2-b1b2 domains, Fc-A22, and Fc-A22p are well prepared. Figure S3: FACS and confocal fluorescence data showing that Fc-A22p, but not Fc, specifically interacts with cell-surface expressed NRP1/2 undergoing cellular internalization. Figure S4: Cell viability data showing that Fc-A22p does not cause significant cytotoxicity on HUVECs and tumor cells. Figure S5: Tumor tissue analyzing data showing that Fc-A22p homes to tumor, induces vascular permeability, and downregulates VE-cadherin in endothelial cells and E-cadherin in tumor cells. Figure S6: Confocal fluorescence data showing that Fc-A22p causes downregulation of VE-/E-cadherin and their dissociation from F-actin cytoskeleton resulting in disruption of cell-cell contacts. Figure S7: Data showing the expression and biochemical characterization of mAb-A22p antibodies, cetuximab-A22p and trastuzumab-A22p, compared with the parent mAbs. Figure S8: Cell proliferation and Western blotting data showing that cetuximab-A22p exerts in vitro biological activities comparable to those of cetuximab in A431 and FaDu tumor cells. Figure S9: Human tumor xenografted mouse data showing that mAb-A22p antibodies show increased tumor homing and penetration and thus superior in vivo anti-tumor efficacy, compared with the parent mAbs. Table S1: SPR data showing the kinetic binding parameters for the interactions of Fc-A22, Fc-A22p, VEGF165, and Sema3A with soluble NRP1-b1b2 and NRP2-b1b2 fragments. Table S2: Purification yields of Fc proteins and antibodies obtained from transient expression in HEK293F cells. Table S3: SPR data showing the kinetic binding parameters for the interactions of mAbs and mAb-A22p antibodies with the indicated proteins. Supplementary Materials and Methods: Detailed description of Reagents; Recombinant protein expression and purification; Construction, expression, and purification of antibodies; Binding analysis by ELISA; Surface plasmon resonance (SPR); Flow cytometric analysis; Cell proliferation assay; Western blotting and immunoprecipitation; Co-localization studies by confocal immunofluorescence microscopy; RNA Interference; Ex vivo tumor penetration assays.
Supplemental Figures 1 through 6 from Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2
Authors: Soares Heloisa P. , Ming Ming , Mellon Michelle , Young Steven H. , Han Liang , Sinnet-Smith James , Rozengurt Enrique
Published: April 2023

Supplemental Figure S1 Structure of NVP-BEZ235; PKI-587; GDC-0980; PD0325901 and U0126. Supplemental Figure S2 NPV-BEZ235 induces over-activation of ERK phosphorylation in MiaPaCa-2 (A) and PANC-1 (B) cells Supplemental Figure S3 The MEK inhibitor PD 0325901 suppresses ERK over-activation induced by NPV-BEZ235 at nanomol S4 Overactivation of MEK phosphorylation by combination of dual PI3K/mTOR kinase inhibitor NPV-BEZ235 and MEK inhibitor PD0325901 Supplemental Figure S5 Dual PI3K/mTOR kinase inhibitors NVP-BEZ235, PKI-587 and GDC-0980 suppress PIP3 accumulation in PDAC cells in different times of stimulation Supplemental Figure S6 NPV-BEZ235 enhances ERK pathway activation through a pathway that does not require EGFR, HER2 or insulin/IGF-1 receptor
Supplementary Figure 1 from Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer
Authors: Zhu Yezi , Liu Chengfei , Nadiminty Nagalakshmi , Lou Wei , Tummala Ramakumar , Evans Christopher P. , Gao Allen C.
Published: April 2023

PDF - 30KB, Down regulation of ABCB1 in docetaxel resistant DU145-R cells reverses docetaxel resistance.
Supplementary Tables 1 through 3 from Leelamine Mediates Cancer Cell Death through Inhibition of Intracellular Cholesterol Transport
Authors: Kuzu Omer F. , Gowda Raghavendra , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 92K, Supplementary Table 1: Compounds and their sources. Supplementary Table 2: Antibodies and their sources. Supplementary Table 3: siRNA sequences and their sources.
Supplementary Table 4 from Leelamine Mediates Cancer Cell Death through Inhibition of Intracellular Cholesterol Transport
Authors: Kuzu Omer F. , Gowda Raghavendra , Sharma Arati , Robertson Gavin P.
Published: April 2023

XLSX - 256K, Kinexus Protein Array Data.
Supplementary Figure 5 from Leelamine Mediates Cancer Cell Death through Inhibition of Intracellular Cholesterol Transport
Authors: Kuzu Omer F. , Gowda Raghavendra , Sharma Arati , Robertson Gavin P.
Published: April 2023

PDF - 82K, Ingenuity Pathway Analyses.
Supplementary Table 1 from Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor
Authors: Xiao Yang , Ramiscal Judi , Kowanetz Kaska , Del Nagro Christopher , Malek Shiva , Evangelista Marie , Blackwood Elizabeth , Jackson Peter K. , O'Brien Thomas
Published: April 2023

PDF - 32KB, In vitro kinase selectivity profile of GNE-783.
Supplementary Tables 1 - 2 from Interferon-β Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells
Authors: Happold Caroline , Roth Patrick , Silginer Manuela , Florea Ana-Maria , Lamszus Katrin , Frei Karl , Deenen Rene , Reifenberger Guido , Weller Michael
Published: April 2023

PDF file - 76KB, Table S1. Altered gene expression of IFN-beta-related and apoptosis-related genes induced by IFN-beta detected by Affymetrix microarray-based gene expression profiling. Table S2. Altered gene expression of growth-related genes in LTL and GIC induced by IFN-beta detected by Affymetrix microarray-based gene expression profiling.
Supplementary Figure 2 from Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Authors: Stessman Holly A.F. , Baughn Linda B. , Sarver Aaron , Xia Tian , Deshpande Raamesh , Mansoor Aatif , Walsh Susan A. , Sunderland John J. , Dolloff Nathan G. , Linden Michael A. , Zhan Fenghuang , Janz Siegfried , Myers Chad L. , Van Ness Brian G.
Published: April 2023

PDF file - 143K, Gene set enrichment analysis of mouse and human cell lines.
Supplementary Tables 1 through 6 from Identification of Transmembrane Protein 98 as a Novel Chemoresistance-Conferring Gene in Hepatocellular Carcinoma
Authors: Ng Kevin Tak-Pan , Lo Chung Mau , Guo Dong Yong , Qi Xiang , Li Chang Xian , Geng Wei , Liu Xiao Bing , Ling Chang Chun , Ma Yuen Yuen , Yeung Wai Ho , Shao Yan , Poon Ronnie Tung-Ping , Fan Sheung Tat , Man Kwan
Published: April 2023

PDF - 150K, Supplementary Table 1: List of primers. Supplementary Table 2: List of commonly up-regulated genes in drug resistant sublines. Supplementary Table 3: List of commonly down-regulated genes in drug resistant sublines. Supplementary Table 4: List of differential genes with 10-fold changes in MHCC97L/CisR and MHCC97L/DoxR sublines. Supplementary Table 5: Expression pattern of 5 up-regulated differential genes in 37 pairs of HCC patients. Supplementary Table 6: Cox proportional hazard regression analysis.
Supplementary Figure 3 from Protein Kinase D as a Potential Chemotherapeutic Target for Colorectal Cancer
Authors: Wei Ning , Chu Edward , Wipf Peter , Schmitz John C.
Published: April 2023

PDF - 190K, Fig. S3. Effect of kb-NB142-70 on RKO cell cycle, apoptosis, and NF-κB activity.
Supplementary Figure 2 from Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
Authors: Eritja Nuria , Domingo Mónica , Dosil Maria Alba , Mirantes Cristina , Santacana Maria , Valls Joan , Llombart-Cussac Antonio , Matias-Guiu Xavier , Dolcet Xavier
Published: April 2023

PDF - 1218K, Four ECCs (IK, AN3CA, MFE-296 and HEC-1A) were treated with Dovitinib (0.05-0.1-0.5-1-2.5 μmol/L) for 72 hours. Cells were stained with Hoechst. The graph on the right shows the percentage of cells displaying apoptotic nuclei in each condition.
Supplementary Data from Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models
Authors: Laroche-Clary Audrey , Morvan Valérie Le , Yamori Takao , Robert Jacques
Published: April 2023

Supplementary Data from Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models
Supplementary Figure 3 from Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease
Authors: Zhong Lai-Ping , Zhu Dong-Wang , William William N. , Liu Ying , Ma Jie , Yang Cheng-Zhe , Yang Xiao , Wang Li-Zhen , Li Jiang , Myers Jeffrey N. , Lee J. Jack , Zhang Chen-Ping , Zhang Zhi-Yuan
Published: April 2023

PDF file - 2826K, Overall survival (A), disease-free survival (B), locoregional recurrence-free survival (C), and distant metastasis-free survival (D) in 232 OSCC patients with low and high cyclin D1 expression.
Supplementary Figure 1 from The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models
Authors: Foster Paul , Yamaguchi Kyoko , Hsu Pin P. , Qian Fawn , Du Xiangnan , Wu Jianming , Won Kwang-Ai , Yu Peiwen , Jaeger Christopher T. , Zhang Wentao , Marlowe Charles K. , Keast Paul , Abulafia Wendy , Chen Jason , Young Jenny , Plonowski Artur , Yakes F. Michael , Chu Felix , Engell Kelly , Bentzien Frauke , Lam Sanh T. , Dale Stephanie , Yturralde Olivia , Matthews David J. , Lamb Peter , Laird A. Douglas
Published: April 2023

Effects of XL147 on PI3K Signaling Pathway in EGF-Stimulated PC-3 Cells.
Supplementary Figure Legends from Mechanism and Efficacy of Sub–50-nm Tenfibgen Nanocapsules for Cancer Cell–Directed Delivery of Anti-CK2 RNAi to Primary and Metastatic Squamous Cell Carcinoma
Authors: Unger Gretchen M. , Kren Betsy T. , Korman Vicci L. , Kimbrough Tyler G. , Vogel Rachel I. , Ondrey Frank G. , Trembley Janeen H. , Ahmed Khalil
Published: April 2023

PDF - 53K, Legends for Supplemental Figures 1 and 2.
Figure S5 from Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway
Authors: Dhanyamraju Pavan Kumar , Holz Philipp Simon , Finkernagel Florian , Fendrich Volker , Lauth Matthias
Published: April 2023

This file contains data on mRNA expression in xenograft tumors treated with HDAC6 inhibitors.
Supplementary Figure Legends from Syngeneic Murine Ovarian Cancer Model Reveals That Ascites Enriches for Ovarian Cancer Stem-Like Cells Expressing Membrane GRP78
Authors: Mo Lihong , Bachelder Robin E. , Kennedy Margaret , Chen Po-Han , Chi Jen-Tsan , Berchuck Andrew , Cianciolo George , Pizzo Salvatore V.
Published: April 2023

Supplementary Figure Legends
Supplementary Material from APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
Authors: Tsai Cheng-Yu , Sun Si , Zhang Hongying , Local Andrea , Su Yongxuan , Gross Larry A. , Rice William G. , Howell Stephen B.
Published: April 2023

Chemical Synthesis of APTO-253
Figure S3 from MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents
Authors: McDaniel Nellie K. , Cummings Christopher T. , Iida Mari , Hülse Justus , Pearson Hannah E. , Vasileiadi Eleana , Parker Rebecca E. , Orbuch Rachel A. , Ondracek Olivia J. , Welke Noah B. , Kang Grace H. , Davies Kurtis D. , Wang Xiaodong , Frye Stephen V. , Earp H. Shelton , Harari Paul M. , Kimple Randall J. , DeRyckere Deborah , Graham Douglas K. , Wheeler Deric L.
Published: April 2023

Evaluation of MERTK inhibitor UNC2025
Suppl. Table S1 from Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015
Authors: Pollmann Sofie Ellebaek , Calvert Valerie S. , Rao Shruti , Boca Simina M. , Madhavan Subha , Horak Ivan D. , Kjaer Andreas , Petricoin Emanuel F. , Kragh Michael , Poulsen Thomas Tuxen
Published: April 2023

Supplementary Table S1. Total list of detection antibodies used for reverse phase protein array.
Supplementary Methods and Figure Legends from Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance
Authors: Heinrich Anne-Kathrin , Lucas Henrike , Schindler Lucie , Chytil Petr , Etrych Tomáš , Mäder Karsten , Mueller Thomas
Published: April 2023

Supplemental material including synthesis of the polymer-drug conugates and Supplementary Figure Legends.
Supplementary File from The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors
Authors: Harney Allison S. , Karagiannis George S. , Pignatelli Jeanine , Smith Bryan D. , Kadioglu Ece , Wise Scott C. , Hood Molly M. , Kaufman Michael D. , Leary Cynthia B. , Lu Wei-Ping , Al-Ani Gada , Chen Xiaoming , Entenberg David , Oktay Maja H. , Wang Yarong , Chun Lawrence , De Palma Michele , Jones Joan G. , Flynn Daniel L. , Condeelis John S.
Published: April 2023

Supplementary Material and Methods
Abstract 3878: Targeting Hippo-YAP, BRD4 and RAS-MAPK interplay in lung cancer to forestall drug resistance
Authors: Chatterjee Nilanjana , Olivas Victor , Wu Wei , Powell Ben , Bivona Trever
Published: April 2023

Introduction: Identifying parallel survival pathways or compensatory mechanisms that limit the response to targeted therapy is critical to discover effective combinatorial strategies for the treatment of lung cancer and to prevent emergence of drug resistance

Results: Using combination drug screening in a panel of cell line models of non-small cell lung cancer (NSCLC), we identified the tumor suppressor STK11 (aka LKB1) as a molecular biomarker of sensitivity to BET and RAS-MAPK pathway inhibitors combination in NSCLC. We found a small molecule inhibitor of BET (bromodomain and extra terminal) family proteins (BRD4, 3, 2), PLX51107, suppressed BRAF and KRAS mutant NSCLC cell proliferation and in combination with RAS (KRAS G12C), RAF or MEK inhibitor led to pronounced loss in cell viability with potent MYC downregulation and synergistic apoptosis induction in vitro and potent tumor regression or stasis in vivo in several KRAS mutant CDX and PDX mouse models of NSCLC. However, BRAF and KRAS mutant NSCLC cells with co-occurring mutations in STK11 were resistant to BET and RAS, RAF or MEK co-inhibition. To unravel the underlying mechanism of resistance to BET and RAS-MAPK inhibitors upon STK11 loss we modeled STK11 deficiency in BRAF and KRAS mutant NSCLC cells and tumors. We found that STK11 loss creates an unprecedented dependence on YAP/TEAD TFs. STK11 silencing in BRAF and KRAS mutant NSCLC cells resulted in nuclear transfer/activation of the HIPPO pathway effector, YAP, upregulation of the YAP target BIRC5 (aka Survivin) and rescued the synthetic lethality due to BET and RAS, RAF or MEK co-inhibition. Phenocopying STK11 loss, constitutively active YAP (YAP5SA), but not transcriptionally inactive YAP (YAPS94A), mitigated the deleterious effects of BET and RAS, RAF or MEK co-suppression in BRAF and KRAS mutant NSCLC cells with potent upregulation of the pro-survival factor BIRC5. Conversely, we found that co-silencing YAP or TEADs with BETs re-sensitized BRAF and KRAS mutant NSCLC cells with co-occurring mutations in STK11 to BET and RAS-MAPK inhibitors combination and caused synthetic lethality.

Conclusion: This study uncovered a functional interaction between BET proteins, STK11, HIPPO-YAP and RAS-MAPK signaling pathways in lung cancer. These results will help identify combinatorial strategies for treating aberrant RAS-MAPK pathway driven lung cancer more effectively and forestall drug resistance.

Citation Format: Nilanjana Chatterjee, Victor Olivas, Wei Wu, Ben Powell, Trever Bivona. Targeting Hippo-YAP, BRD4 and RAS-MAPK interplay in lung cancer to forestall drug resistance. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3878.
Abstract 705: Potentiation of immunotherapy by LSD1 modulation
Authors: Emond Wei B. , Sawant Rajiv , Geitmann Matthis , Winquist Johan , Brandt Peter , Bremberg Ulf , Källblad Per , Parrow Vendela , Andersson Claes , Blom Kristin , Najafi Nasrin , Bergström Tobias , Swartling Fredrik J. , Hellström Mats , Koehler Konrad F.
Published: April 2023

LSD1 has emerged as a potential therapeutic target to increase the effectiveness of cancer immunotherapy. We have developed a series of novel small molecules, exemplified by the lead substance BEA-17, that modulates LSD1 via binding to an allosteric site, without directly inhibiting its enzymatic activity. In cells, BEA-17 induces a reduction of LSD1 levels. In addition, BEA-17 upregulates the expression of endogenous retroviral genes and T cell-attractant chemokines and does so in an LSD1-dependent manner. In a co-culture of HeLa and PBMCs, BEA-17 increases cell kill of cancer cells by immune effector T cells, also in an LSD1-dependent manner. In a CT26 syngeneic animal model of colon cancer, BEA-17 potentiates the activity of anti-PD1 inhibitors. Finally, in a syngeneic GL261 animal model of glioblastoma, BEA-17 increases the effectiveness of standard-of-care temozolomide + radiation.

Citation Format: Wei B. Emond, Rajiv Sawant, Matthis Geitmann, Johan Winquist, Peter Brandt, Ulf Bremberg, Per Källblad, Vendela Parrow, Claes Andersson, Kristin Blom, Nasrin Najafi, Tobias Bergström, Fredrik J. Swartling, Mats Hellström, Konrad F. Koehler. Potentiation of immunotherapy by LSD1 modulation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 705.
Supplementary Figure 3 from Minocycline Targets the NF-κB Nexus through Suppression of TGF-β1-TAK1-IκB Signaling in Ovarian Cancer
Authors: Ataie-Kachoie Parvin , Badar Samina , Morris David L. , Pourgholami Mohammad H.
Published: April 2023

PDF file - 1507K, Effect of minocycline on constitutive and TNF-α-induce NF-кB activation in HUVEC and HOSE cells.
Supplementary Figure 2 from Minocycline Targets the NF-κB Nexus through Suppression of TGF-β1-TAK1-IκB Signaling in Ovarian Cancer
Authors: Ataie-Kachoie Parvin , Badar Samina , Morris David L. , Pourgholami Mohammad H.
Published: April 2023

PDF file - 2503K, Influence of minocycline on inducible NF-кB activation.
Supplementary Table 4 from Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identifies a Link Between p14ARF and RARβ Signaling
Authors: Dahl Christina , Christensen Claus , Jönsson Göran , Lorentzen Anders , Skjødt Mette Louise , Borg Åke , Pawelec Graham , Guldberg Per
Published: April 2023

PDF file - 51K, Promoter hypermethylation events.
Supplementary Table 1 from Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identifies a Link Between p14ARF and RARβ Signaling
Authors: Dahl Christina , Christensen Claus , Jönsson Göran , Lorentzen Anders , Skjødt Mette Louise , Borg Åke , Pawelec Graham , Guldberg Per
Published: April 2023

PDF file - 74K, Mutations and homozygous deletions.
Supplementary Figure S5 from Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
Authors: Terai Hideki , Soejima Kenzo , Yasuda Hiroyuki , Nakayama Sohei , Hamamoto Junko , Arai Daisuke , Ishioka Kota , Ohgino Keiko , Ikemura Shinnosuke , Sato Takashi , Yoda Satoshi , Satomi Ryosuke , Naoki Katsuhiko , Betsuyaku Tomoko
Published: April 2023

Supplementary Figure S5 - PDF file 109K, Efficient knockdown of FGFR1, FGFR3, and FGF2 with each siRNA confirmed by quantitative RT-PCR
Supplementary Figure S3 from Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC
Authors: Terai Hideki , Soejima Kenzo , Yasuda Hiroyuki , Nakayama Sohei , Hamamoto Junko , Arai Daisuke , Ishioka Kota , Ohgino Keiko , Ikemura Shinnosuke , Sato Takashi , Yoda Satoshi , Satomi Ryosuke , Naoki Katsuhiko , Betsuyaku Tomoko
Published: April 2023

Supplementary Figure S3 - PDF file 139K,The relative expression profiles of mRNA of FGFs by microarray analysis in PC9 GR, PC9 gr1 and PC9 gr3 cells normalized to mRNA extracted from PC9 na cells. None of FGFs other than FGF2 was elevated in gefitinib resistant cell lines. Each group of columns represents the result from one microarray probe
Supplementary Figure Legend from NF-κB Activation-Induced Anti-apoptosis Renders HER2-Positive Cells Drug Resistant and Accelerates Tumor Growth
Authors: Bailey Shannon T. , Miron Penelope L. , Choi Yoon J. , Kochupurakkal Bose , Maulik Gautam , Rodig Scott. J. , Tian Ruiyang , Foley Kathleen M. , Bowman Teresa , Miron Alexander , Brown Myles , Iglehart J. Dirk. , Biswas Debajit K.
Published: April 2023

PDF file - 78K
Supplementary Table 1, Figures 1 - 8 from AURKA Governs Self-Renewal Capacity in Glioma-Initiating Cells via Stabilization/Activation of β-catenin/Wnt Signaling
Authors: Xia Zhibo , Wei Ping , Zhang Heng , Ding Zhiming , Yang Lixuan , Huang Zhengsong , Zhang Nu
Published: April 2023

PDF file - 2835K, Supplementary Table 1. Differentially regulated Wnt signaling genes by AURKA identified by q-PCR. Supplementary Fig. 1. AURKA and stem cell markers' expressions in mouse model tumor samples. Supplementary Fig. 2. Stem cell markers and differentiation markers were stained after beta-catenin S33Y mutation transfected in stable AURKA knockdown cells. Supplementary Fig. 3. The mRNA levels of beta-catenin in GIC cells that stably expressed control sh-RNA or AURKA-shRNA were detected by q-PCR. Bars from three independent experiments. Supplementary Fig. 4. The stable GSCs that expressed the vector alone and sh-AA-1 were treated with cycloheximide (20 microM) for the indicated time points, and the total proteins were harvested. Supplementary Fig. 5. AXIN siRNA was transiently transfected into the indicated cells using Lipofectamine 2000 in accordance with the manufacturer's instructions. Supplementary Fig. 6. Representative photos of paraffin-embedded specimens of 40 WHO grade IV glioblastomas were stained by immunohistochemistry using anti-AURKA and anti-beta-catenin antibody. Amplifications are 200X; bars represent 200 microM. Supplementary Fig. 7. Cell cycle turnover of GIC cells that stably express control sh-RNA or AURKA-shRNA was decided by flow cytometry. Supplementary Fig. 8. The apoptosis ratio was not influenced after AURKA inhibition in GSC.
Supplementary Tables 1 - 2 from RASSF1A-Mediated Regulation of AREG via the Hippo Pathway in Hepatocellular Carcinoma
Authors: Ahn Ei Yong , Kim Ji Su , Kim Gi Jeong , Park Young Nyun
Published: April 2023

PDF file - 122K, Clinical and pathological findings of HCC patients, and the expression level of YAP and AREG detected by western blot analysis in hepatocellular carcinoma patients.
Supplementary Table 2 from Comparative microRNA Profiling of Prostate Carcinomas with Increasing Tumor Stage by Deep Sequencing
Authors: Hart Martin , Nolte Elke , Wach Sven , Szczyrba Jaroslaw , Taubert Helge , Rau Tilman T. , Hartmann Arndt , Grässer Friedrich A. , Wullich Bernd
Published: April 2023

PDF file - 25K, List of sequences of cloning primers, mutagenesis primers, and Northern blotting probes.
Supplementary Figure 2 from RASSF1A-Mediated Regulation of AREG via the Hippo Pathway in Hepatocellular Carcinoma
Authors: Ahn Ei Yong , Kim Ji Su , Kim Gi Jeong , Park Young Nyun
Published: April 2023

PDF file - 2527K, Relationship between RASSF1A, YAP, and AREG histoscores.